BACKGROUND: Mortality between stage I and II palliation for hypoplastic left heart syndrome (HLHS) has been associated with arrhythmias. The stage-related proportion, associations, and clinical impact of arrhythmias in patients with HLHS have not been evaluated. In addition, arrhythmia subtypes have not been described in this patient group. METHODS: We performed a retrospective analysis of all patients at Duke University Medical Center who received one or more palliative stages for HLHS from September 2000 to October 2008. RESULTS: Overall, 49 (57%) of 86 patients had 63 arrhythmias. The majority of arrhythmias occurred between stage I and II, with 44 (51%) of 86 patients manifesting a new arrhythmia. Arrhythmias occurring in this interval tended to be associated with a higher mortality compared with arrhythmias occurring after stage II (odds ratio = 3.2 [95% CI 0.84-12.0], P = .09). Overall mortality was similar in patients with and without arrhythmias (P = .99). Supraventricular tachycardia was the most common arrhythmia (16/63; 25%), but persistent bradycardias (sinus node dysfunction or high-grade atrioventricular block) had the worst clinical outcome with 73% mortality (8/11). There was no association between arrhythmia occurrence and degree of tricuspid regurgitation, left ventricular hypertension, genetic syndrome, type of stage I operation, or need for extracorporeal membrane oxygenation. CONCLUSIONS: A large proportion of patients with HLHS experience serious arrhythmias requiring therapy, especially between stage I and II. Persistent bradycardia following stage I is associated with a high mortality rate. Considering all arrhythmia patients, overall mortality was not different compared with the arrhythmia-free group.
BACKGROUND: Mortality between stage I and II palliation for hypoplastic left heart syndrome (HLHS) has been associated with arrhythmias. The stage-related proportion, associations, and clinical impact of arrhythmias in patients with HLHS have not been evaluated. In addition, arrhythmia subtypes have not been described in this patient group. METHODS: We performed a retrospective analysis of all patients at Duke University Medical Center who received one or more palliative stages for HLHS from September 2000 to October 2008. RESULTS: Overall, 49 (57%) of 86 patients had 63 arrhythmias. The majority of arrhythmias occurred between stage I and II, with 44 (51%) of 86 patients manifesting a new arrhythmia. Arrhythmias occurring in this interval tended to be associated with a higher mortality compared with arrhythmias occurring after stage II (odds ratio = 3.2 [95% CI 0.84-12.0], P = .09). Overall mortality was similar in patients with and without arrhythmias (P = .99). Supraventricular tachycardia was the most common arrhythmia (16/63; 25%), but persistent bradycardias (sinus node dysfunction or high-grade atrioventricular block) had the worst clinical outcome with 73% mortality (8/11). There was no association between arrhythmia occurrence and degree of tricuspid regurgitation, left ventricular hypertension, genetic syndrome, type of stage I operation, or need for extracorporeal membrane oxygenation. CONCLUSIONS: A large proportion of patients with HLHS experience serious arrhythmias requiring therapy, especially between stage I and II. Persistent bradycardia following stage I is associated with a high mortality rate. Considering all arrhythmiapatients, overall mortality was not different compared with the arrhythmia-free group.
Authors: R J Kanter; J Papagiannis; M P Carboni; R M Ungerleider; W E Sanders; J M Wharton Journal: J Am Coll Cardiol Date: 2000-02 Impact factor: 24.094
Authors: M I Cohen; N D Bridges; J W Gaynor; T M Hoffman; G Wernovsky; V L Vetter; T L Spray; L A Rhodes Journal: J Thorac Cardiovasc Surg Date: 2000-11 Impact factor: 5.209
Authors: N S Ghanayem; G M Hoffman; K A Mussatto; J R Cava; P C Frommelt; N A Rudd; M M Steltzer; S M Bevandic; S S Frisbee; R D B Jaquiss; S B Litwin; J S Tweddell Journal: J Thorac Cardiovasc Surg Date: 2003-11 Impact factor: 5.209
Authors: Timothy M Hoffman; David M Bush; Gil Wernovsky; Mitchell I Cohen; Tammy S Wieand; J William Gaynor; Thomas L Spray; Larry A Rhodes Journal: Ann Thorac Surg Date: 2002-11 Impact factor: 4.330
Authors: David A Hehir; Troy E Dominguez; Jean A Ballweg; Chitra Ravishankar; Bradley S Marino; Geoffrey L Bird; Susan C Nicolson; Thomas L Spray; J William Gaynor; Sarah Tabbutt Journal: J Thorac Cardiovasc Surg Date: 2008-05-22 Impact factor: 5.209
Authors: Matthew E Oster; Shan Chen; Nicholas Dagincourt; Yaniv Bar-Cohen; Matthew Brothers; Nicole Cain; Steven D Colan; Richard J Czosek; Jamie A Decker; David G Gamboa; Salim F Idriss; Joel A Kirsh; Martin J LaPage; Richard G Ohye; Elizabeth Radojewski; Maully Shah; Eric S Silver; Anoop K Singh; Joel D Temple; John Triedman; Jonathan R Kaltman Journal: J Thorac Cardiovasc Surg Date: 2016-11-16 Impact factor: 5.209
Authors: Carolyn M Wilhelm; Diane Paulus; Clifford L Cua; Naomi J Kertesz; John P Cheatham; Mark Galantowicz; Richard P Fernandez Journal: Pediatr Cardiol Date: 2015-12-14 Impact factor: 1.655
Authors: Eric J Hall; Andrew H Smith; Frank A Fish; David P Bichell; Bret A Mettler; Kimberly Crum; Prince J Kannankeril; Andrew E Radbill Journal: Ann Thorac Surg Date: 2017-09-28 Impact factor: 4.330
Authors: Nadya Golfenshtein; Alexandra L Hanlon; Janet A Deatrick; Barbara Medoff-Cooper Journal: Congenit Heart Dis Date: 2019-10-27 Impact factor: 2.007
Authors: Megan C McFerson; Anthony C McCanta; Zhaoxing Pan; Kathryn K Collins; James Jaggers; Eduardo M da Cruz; Jon Kaufman Journal: Pediatr Cardiol Date: 2013-11-17 Impact factor: 1.655